Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders

Blood

Volumn 98, Issue 6, 2001, Pages 1842-1846

  Moore, Jane C ^a   Hayward, Catherine P M ^a,b   Warkentin, Theodore E ^a   Kelton, John G ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; METALLOPROTEINASE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME ACTIVITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKEMIA; MAJOR CLINICAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0035885931     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1842     Document Type: Article

References (28)

1. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57:1140-1143.
2. Tsai H-M, Nagel RL, Hatcher VB, Sussman II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989;73:2074-2076.
3. Dent JA, Berowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990;87:6306-6310.
4. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand Factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
5. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
6. Tsai H-M. Physiological cleavage of von Willebrand factor by a plasma protease is dependent on its confirmation and requires calcium ion. Blood. 1996;87:4235-4244.
7. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
8. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenia and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
9. Mannucci PM, Lombardi R, Lattuada A, et al. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura. Blood. 1989;74:978-983.
10. Moake JL, von Willebrand factor in the pathophysiology of thrombotic thrombocytopenic purpura. Clin Lab Sci. 1998;11:362-372.
11. Moore JC, Murphy WG, Kelton JG. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Haematol. 1990;74:457-464.
12. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:496-507.
13. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435.
14. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving activity in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103.
15. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with specific reference to factor VIII related antigen. Thromb Res. 1985;38:469-479.
16. Tsai H-M, Lian EC-Y. Inhibitors to vWF-cleaving metalloproteinase in thrombotic thrombocytopenic purpura [abstract]. Blood. 1997;90(suppl 1):2620.
17. Krause M, Furlan M, Ehrenforth S. Relevance of the von Willebrand factor cleaving protease in the diagnosis and clinical course in patients with thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS) [abstract]. Blood. 1997;90(suppl 1):404.
18. Murphy WG, Moore JC, Barr RD, Pal MKR, Kelton JG. Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. Br J Haematol. 1987;66:509-513.
19. Gerritsen H, Turecek P, Schwarz HP, Lammle BL, Furlan M. Assay of von Willebrand factor (vWF)cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-1389.
20. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost.1999;82:1382-1385.
21. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med.1991;325:393-397.
22. Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood. 1982;60:1030-1037.
23. Leung DY, Moake JL, Havens PL, Kim M, Pober JS. Lytic anti-endothelial antibodies in haemolytic-uraemic syndrome. Lancet. 1988;2:183-186,
24. Lian EC, Siddiqui FA, Jamieson GA, Tandon NN, Platelet agglutinating protein p37 causes platelet activation through its binding to membrane glycoprotein IV. Thromb Haemost. 1991;65:102-106.
25. Kelton JG, Moore JC, Murphy WG. Studies investigating platelet aggregation and release initiated by sera from patients with thrombotic thrombocytopenic purpura. Blood. 1987;69:924-928.
26. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol. 1994;88:816-825.
27. Schultz DR, Arnold PI, Jy W, et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura amd other thrombocytopenic disorders: identification of an 85-kD form of CD36 as a target antigen. Br J Haematol. 1998;103:849-857.
28. Kelton JG, Warkentin TE, Hayward CPM, Murphy WG, Moore JC, Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood. 1992;80:2246-2251.